Neuphoria Therapeutics Inc
NEUP7.940USD
-0.110-1.37%
Market hours （ET）Quotes delayed by 15 min
14.72MMarket Cap
1.73P/E TTM
More Details of Neuphoria Therapeutics Inc Company
Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
Company Info
Ticker SymbolNEUP
Company nameNeuphoria Therapeutics Inc
IPO dateDec 21, 1999
CEODr. Spyridon (Spyros) Papapetropoulos, M.D.
Number of employees8
Security typeOrdinary Share
Fiscal year-endDec 21
Address100 Summit Dr
CityBURLINGTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01803
Phone
Websitehttps://www.neuphoriatx.com/
Ticker SymbolNEUP
IPO dateDec 21, 1999
CEODr. Spyridon (Spyros) Papapetropoulos, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Miles Winston (Miles Davies) Davies
Mr. Peter Miles Winston (Miles Davies) Davies
Non-Executive Independent Director
Non-Executive Independent Director
269.98K
--
Mr. David Ian Wilson
Mr. David Ian Wilson
Non-Executive Director
Non-Executive Director
251.94K
--
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Liz Doolin
Ms. Liz Doolin
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Jane Ryan, Ph.D.
Dr. Jane Ryan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Alan Fisher
Mr. Alan Fisher
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Miles Winston (Miles Davies) Davies
Mr. Peter Miles Winston (Miles Davies) Davies
Non-Executive Independent Director
Non-Executive Independent Director
269.98K
--
Mr. David Ian Wilson
Mr. David Ian Wilson
Non-Executive Director
Non-Executive Director
251.94K
--
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
Dr. Spyridon (Spyros) Papapetropoulos, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Liz Doolin
Ms. Liz Doolin
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Jane Ryan, Ph.D.
Dr. Jane Ryan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Australia
165.49K
0.00%
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Apeiron Investment Group Ltd
3.86%
AdvisorShares Investments, LLC
3.71%
Lynx1 Capital Advisors LLC
2.44%
Prosperity Wealth Management, Inc.
1.45%
Merck & Co Inc
0.53%
Other
88.02%
Shareholders
Shareholders
Proportion
Apeiron Investment Group Ltd
3.86%
AdvisorShares Investments, LLC
3.71%
Lynx1 Capital Advisors LLC
2.44%
Prosperity Wealth Management, Inc.
1.45%
Merck & Co Inc
0.53%
Other
88.02%
Shareholder Types
Shareholders
Proportion
Individual Investor
33.08%
Investment Advisor
8.14%
Family Office
3.86%
Corporation
0.53%
Other
54.38%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
33
6.78M
41.76%
+3.57M
2025Q1
33
6.78M
41.76%
+3.58M
2024Q4
32
7.37M
43.34%
+1.92M
2024Q3
28
10.93M
60.28%
+6.68M
2024Q2
22
3.20M
28.02%
+971.25K
2024Q1
21
2.12M
20.11%
-221.89K
2023Q4
19
2.39M
22.66%
-332.20K
2023Q3
16
3.51M
33.26%
+2.99M
2023Q2
8
471.38K
5.30%
-62.88K
2023Q1
8
490.12K
5.57%
-204.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Apeiron Investment Group Ltd
72.62K
3.86%
-592.38K
-89.08%
Jan 24, 2025
AdvisorShares Investments, LLC
69.66K
3.71%
+22.00K
+46.16%
Mar 31, 2025
Lynx1 Capital Advisors LLC
45.81K
2.44%
--
--
Mar 31, 2025
Prosperity Wealth Management, Inc.
27.20K
1.45%
+27.20K
--
Mar 31, 2025
Merck & Co Inc
10.03K
0.53%
--
--
Mar 31, 2025
Cyndeo Wealth Partners, LLC
10.00K
0.53%
+10.00K
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
415.00
0.02%
-691.00
-62.48%
Mar 31, 2025
Morgan Stanley & Co. LLC
7.00
0%
--
--
Mar 31, 2025
Hanson & Doremus Investment Management, Inc.
--
0%
-1.00
-100.00%
Mar 31, 2025
Two Sigma Investments, LP
--
0%
-42.41K
-100.00%
Sep 30, 2024
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Psychedelics ETF
4.65%
AdvisorShares Psychedelics ETF
Proportion4.65%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
